Abstract
The dual face of NAMPT: Intracellular/extracellular protein and diagnostic/therapeutic target in cancer.
Highlights
Since the discovery of nicotinamide phosphoribosyltransferase (NAMPT) as a pre-B cell-enhancing factor in 1994 by Samal et al [1], many papers have described the pleiotropic function of this enzyme
A vital role of NAMPT in mammalian cells was attributed to its activity as a rate-limiting enzyme in the biosynthesis of nicotinamide adenine dinucleotide (NAD) from nicotinamide, and was supported by its widespread tissue distribution and by the embryonic lethality of total NAMPT knock-out mice [2]
It is clear in the field that it is necessary to select tumours uniquely addicted to NAMPT activity in the generation of NAD
Summary
Since the discovery of nicotinamide phosphoribosyltransferase (NAMPT) as a pre-B cell-enhancing factor in 1994 by Samal et al [1], many papers have described the pleiotropic function of this enzyme. A common strategy that several tumour types adopt to sustain NAD production is to overexpress NAMPT, regulated at the transcriptional level [5].
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
